Shots:
The P-II (DX-211) study evaluates the safety & efficacy of topical OCS-01 in patients with DME. Oculis is currently evaluating OSC-01 in an ongoing P-III (DIAMOND) trial
The results from the study demonstrated that OCS-01 was superior to the vehicle in the primary efficacy analysis of BCVA change from baseline with a group difference of +1.58 ETDRS letters at the pre-specified significance level of 0.15 indicating reduced central macular thickness & improved visual acuity
The mean CMT showed a great decline from baseline in the OSC-01 group vs. vehicle at all post-baseline time points (≤12wks.) & reversed towards baseline with treatment stopped at 12wks. indicating an effect of ONS-01 on retinal edema
Ref: GlobeNewswire | Image: Oculis
